PHE - Corporate - Newborn Screening for Cystic Fibrosis
Determining the impact of employing next generation genomic sequencing (NGS) as part of the method of newborn screening for Cystic Fibrosis (CF): a stakeholder engagement project
Buyer
UK Health Security Agency
Value
£99,696
Published
4 Nov 2021
Closes
27 Aug 2021
Procurement details
Source
Contracts Finder
Region
Tower Hamlets
Procurement method
Other
Category
Services
Contract starts
1 Nov 2021
Contract ends
30 Nov 2022
CPV classifications
75122000
Administrative healthcare services
Lots
Lot default PHE - Corporate - Newborn Screening for Cystic Fibrosis
£99,696
Determining the impact of employing next generation genomic sequencing (NGS) as part of the method of newborn screening for Cystic Fibrosis (CF): a stakeholder engagement project
Delivery: British Oversea Territories, Channel Islands, Europe, Isle of Man, Rest of the World, United Kingdom
Documents
Unlock document linkAwarded contract notice on Contracts Finder
4 Nov 2021
Awarded contract notice on Contracts Finder
Award notice · Web page
Contains public sector information licensed under the Open Government Licence v3.0.